Cont C1 pharmaceutical composition, wherein said gallic acid ester is selected from the group consisting of (-)-epicatechin gallate, (-)-epigallocatechin gallate, (-)-gallocatechin gallate, and tannic acid.

Please add new claims 58 and 59 :

C2 58. A method of formulating an oral pharmaceutical composition, the method comprising:

admixing a pharmaceutical compound, a pharmaceutical carrier, and a gallic acid ester, the gallic acid ester being present in sufficient amount to provide bioavailability of the pharmaceutical compound in the presence of the gallic acid ester greater than the bioavailability of the pharmaceutical compound in the absence of the gallic acid ester when the pharmaceutical composition is administered orally to a mammal, wherein said gallic acid ester is selected from the group consisting of (-)-epicatechin gallate, (-)-epigallocatechin gallate and (-)-gallocatechin gallate.

59. A method of reformulating an existing oral pharmaceutical composition, the method comprising:

admixing the active compound of the existing oral pharmaceutical composition with a gallic acid ester, the gallic acid ester being present in sufficient amount to provide bioavailability of the active compound when administered in the reformulated composition greater than said bioavailability of the active compound when administered in the existing pharmaceutical composition, wherein said gallic acid ester is selected from the group consisting of (-)-epicatechin gallate, (-)-epigallocatechin gallate and (-)-gallocatechin gallate.

REMARKS

In the claims

Claim 43 has been amended and new claims 58 and 59 have been added. No new matter has been introduced in these claims.

Election/Restrictions

In response to the restriction requirement, Applicant elects, with traverse, the claims of Group II (claims 23, 32-36, 38-40, and 52-55) for further prosecution. Applicant also requests